



Published in final edited form as:

Nature. 2021 August ; 596(7870): 109–113. doi:10.1038/s41586-021-03738-2.

SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses

Jackson S. Turner^{1,12}, Jane A. O'Halloran^{2,12}, Elizaveta Kalaidina³, Wooseob Kim¹, Aaron J. Schmitz¹, Julian Q. Zhou¹, Tingting Lei¹, Mahima Thapa¹, Rita E. Chen^{1,4}, James Brett Case⁴, Fatima Amanat^{5,6}, Adriana M. Rauseo², Alem Haile⁷, Xuping Xie⁸, Michael K. Klebert⁷, Teresa Suessen⁹, William D. Middleton⁹, Pei-Yong Shi⁸, Florian Krammer⁵, Sharlene A. Teefey⁹, Michael S. Diamond^{4,10,11}, Rachel M. Presti^{2,10,∞}, Ali H. Ellebedy^{1,10,11,∞}

¹Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA

²Division of Infectious Diseases, Department of Internal Medicine, Washington University School of Medicine, St Louis, MO, USA

³Division of Allergy and Immunology, Department of Internal Medicine, Washington University School of Medicine, St Louis, MO, USA

⁴Department of Medicine, Washington University School of Medicine, St Louis, MO, USA

⁵Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA

⁶Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA

⁷Clinical Trials Unit, Washington University School of Medicine, St Louis, MO, USA

Reprints and permissions information is available at <http://www.nature.com/reprints>.

[∞]**Correspondence and requests for materials** should be addressed to R.M.P. or A.H.E. prestir@wustl.edu; ellebedy@wustl.edu.

Author contributions

A.H.E., J.A.O. and R.M.P. conceived and designed the study. J.A.O., A.H., M.K.K. and R.M.P. wrote and maintained the Institutional Review Board protocol, recruited and phlebotomized participants, and coordinated sample collection. J.S.T., E.K., W.K., A.J.S. and T.L. processed specimens. J.S.T., E.K., W.K. and A.J.S. performed ELISA and ELISpot. R.E.C. and J.B.C. performed neutralization assays. J.S.T., E.K., W.K., A.J.S., T.L. and M.T. generated and characterized monoclonal antibodies. A.J.S. performed RNA extractions and library preparation for B cell receptor bulk sequencing. J.Q.Z. analysed B cell receptor repertoire data. T.S. and W.D.M. performed FNA. W.D.M. and S.A.T. supervised lymph node evaluation prior to FNA and specimen collection and evaluated lymph node ultrasound data. A.J.S. expressed SARS-CoV-2 S and RBD proteins. F.A. and F.K. expressed coronavirus S proteins. J.S.T. sorted cells and collected and analysed the flow cytometry data. X.X. and P.-Y.S. prepared the SARS-CoV-2 with variant S mutations. J.S.T., A.M.R. and A.H.E. analysed the data. M.S.D. and A.H.E. supervised experiments and obtained funding. J.S.T. and A.H.E. composed the manuscript. All authors reviewed the manuscript.

Online content

Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41586-021-03738-2>.

Reporting summary

Further information on research design is available in the Nature Research Reporting Summary linked to this paper.

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41586-021-03738-2>.

Peer review information *Nature* thanks the anonymous reviewers for their contribution to the peer review of this work. Peer reviewer reports are available.

⁸University of Texas Medical Branch, Galveston, TX, USA

⁹Mallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, MO, USA

¹⁰Center for Vaccines and Immunity to Microbial Pathogens, Washington University School of Medicine, St Louis, MO, USA

¹¹The Andrew M. and Jane M. Bursky Center for Human Immunology & Immunotherapy Programs, Washington University School of Medicine, St Louis, MO, USA

¹²These authors contributed equally: Jackson S. Turner, Jane A. O'Halloran

Abstract

SARS-CoV-2 mRNA-based vaccines are about 95% effective in preventing COVID-19¹⁻⁵. The dynamics of antibody-secreting plasmablasts and germinal centre B cells induced by these vaccines in humans remain unclear. Here we examined antigen-specific B cell responses in peripheral blood ($n = 41$) and draining lymph nodes in 14 individuals who had received 2 doses of BNT162b2, an mRNA-based vaccine that encodes the full-length SARS-CoV-2 spike (*S*) gene¹. Circulating IgG- and IgA-secreting plasmablasts that target the S protein peaked one week after the second immunization and then declined, becoming undetectable three weeks later. These plasmablast responses preceded maximal levels of serum anti-S binding and neutralizing antibodies to an early circulating SARS-CoV-2 strain as well as emerging variants, especially in individuals who had previously been infected with SARS-CoV-2 (who produced the most robust serological responses). By examining fine needle aspirates of draining axillary lymph nodes, we identified germinal centre B cells that bound S protein in all participants who were sampled after primary immunization. High frequencies of S-binding germinal centre B cells and plasmablasts were sustained in these draining lymph nodes for at least 12 weeks after the booster immunization. S-binding monoclonal antibodies derived from germinal centre B cells predominantly targeted the receptor-binding domain of the S protein, and fewer clones bound to the N-terminal domain or to epitopes shared with the S proteins of the human betacoronaviruses OC43 and HKU1. These latter cross-reactive B cell clones had higher levels of somatic hypermutation as compared to those that recognized only the SARS-CoV-2 S protein, which suggests a memory B cell origin. Our studies demonstrate that SARS-CoV-2 mRNA-based vaccination of humans induces a persistent germinal centre B cell response, which enables the generation of robust humoral immunity.

The concept of using mRNAs as vaccines was introduced over 30 years ago^{6,7}. Key refinements that improved the biological stability and translation capacity of exogenous mRNA enabled development of these molecules as vaccines^{8,9}. The emergence of SARS-CoV-2 in December 2019, and the ensuing pandemic, has revealed the potential of this platform⁹⁻¹¹. Hundreds of millions of people have received one of the two SARS-CoV-2 mRNA-based vaccines that were granted emergency use authorization by the US Food and Drug Administration in December 2020. Both of these vaccines demonstrated notable immunogenicity in phase-I/II studies and efficacy in phase-III studies^{1-4,12-14}. Whether these vaccines induce the robust and persistent germinal centre reactions that are critical for generating high-affinity and durable antibody responses has not been examined in humans. To address this question, we conducted an observational study of 41 healthy adults

(8 of whom had a history of confirmed SARS-CoV-2 infection) who received the Pfizer–BioNTech SARS-CoV-2 mRNA vaccine BNT162b2 (Extended Data Tables 1, 2). Blood samples were collected at baseline, and at weeks 3 (pre-boost), 4, 5, 7 and 15 after the first immunization. Fine needle aspirates (FNAs) of the draining axillary lymph nodes were collected from 14 participants (none with history of SARS-CoV-2 infection) at weeks 3 (pre-boost), 4, 5, 7, and 15 after the first immunization (Fig. 1a).

We used an enzyme-linked immune absorbent spot (ELISpot) assay to measure antibody-secreting plasmablasts in blood that bound SARS-CoV-2 S protein. We detected SARS-CoV-2-S-specific IgG- and IgA-secreting plasmablasts 3 weeks after primary immunization in 24 of 33 participants with no history of SARS-CoV-2 infection, but in 0 of 8 participants who had previously been infected with SARS-CoV-2. Plasmablasts peaked in blood during the first week after boosting (week 4 after primary immunization), with frequencies that varied widely from 3 to 4,100 S-binding plasmablasts per 10^6 peripheral blood mononuclear cells (PBMCs) (Fig. 1b, c). We found that plasma IgG antibody titres against S, measured by enzyme-linked immunosorbent assay (ELISA), increased in all participants over time, and reached peak geometric mean half-maximal binding titres of 5,567 and 15,850 at 5 weeks after immunization among participants without and with history of SARS-CoV-2 infection, respectively, with a subsequent decline by 15 weeks after immunization. Anti-S IgA titres and IgG titres against the receptor-binding domain (RBD) of S showed similar kinetics, and reached peak geometric mean half-maximal binding titres of 172 and 739 for anti-S IgA and 4,501 and 7,965 for anti-RBD IgG among participants without and with history of SARS-CoV-2 infection, respectively, before declining. IgM responses were weaker and more transient, peaking 4 weeks after immunization among participants without history of SARS-CoV-2 infection with a geometric mean half-maximal binding titre of 78 and were undetectable in all but 2 previously infected participants (Fig. 1d, Extended Data Fig. 1a).

The functional quality of serum antibody was measured using high-throughput focus reduction neutralization tests¹⁵ on Vero cells expressing TMPRSS2 against three authentic infectious SARS-CoV-2 strains with sequence variations in the *S* gene^{16,17}: (1) a Washington strain (2019n-CoV/USA) with a prevailing D614G substitution (WA1/2020 D614G); (2) a B.1.1.7 isolate with signature changes in the *S* gene¹⁸, including mutations resulting in the deletion of residues 69, 70, 144 and 145 as well as N501Y, A570D, D614G and P681H substitutions; and (3) a chimeric SARS-CoV-2 with a B.1.351 *S* gene in the Washington strain background (Wash-B.1.351) that contained the following changes: D80A, deletion of residues 242–244, R246I, K417N, E484K, N501Y, D614G and A701V. Serum neutralizing titres increased markedly in participants without a history of SARS-CoV-2 infection after boosting, with geometric mean neutralization titres against WA1/2020 D614G of 58 at 3 weeks after primary immunization and 572 at 2 or 4 weeks after boost (5 or 7 weeks after primary immunization). Neutralizing titres against the B.1.1.7 and B.1.351 variants were lower, with geometric mean neutralization titres of 49 and 373 against B.1.1.7 and 36 and 137 against B.1.351 after primary and secondary immunization, respectively. In participants with a history of previous SARS-CoV-2 infection, neutralizing titres against all three viruses were detected at baseline (geometric mean neutralization titres of 241.8, 201.8 and 136.7 against WA1/2020 D614G, B.1.1.7 and B.1.351, respectively). In these participants, neutralizing titres increased more rapidly and to higher levels after

immunization, with geometric mean neutralization titres of 4,544, 3,584 and 1,897 against WA1/2020 D614G, B.1.1.7 and B.1.351, respectively, after primary immunization, and 9,381, 9,351 and 2,749 against WA1/2020 D614G, B.1.1.7 and B.1.351, respectively, after secondary immunization. These geometric mean neutralization titres were 78-, 73- and 53-fold higher after primary immunization and 16-, 25- and 20-fold higher after boosting against WA1/2020 D614G, B.1.1.7 and B.1.351, respectively, than in participants without a history of SARS-CoV-2 infection (Extended Data Fig. 1b).

The BNT162b2 vaccine is injected into the deltoid muscle, which drains primarily to the lateral axillary lymph nodes. We used ultrasonography to identify and guide FNA of accessible axillary nodes on the side of immunization approximately 3 weeks after primary immunization. In 5 of the 14 participants, a second draining lymph node was identified and sampled after secondary immunization (Fig. 2a). Germinal centre B cells (defined as CD19⁺CD3⁻IgD^{low}BCL6⁺CD38^{int} lymphocytes) were detected in all lymph nodes (Fig. 2b, d, Extended Data Fig. 2a, Extended Data Table 3). We co-stained FNA samples with two fluorescently labelled S probes to detect S-binding germinal centre B cells. A control tonsillectomy sample with a high frequency of germinal centre B cells that was collected before the COVID-19 pandemic from an unrelated donor was stained as a negative control. S-binding germinal centre B cells were detected in FNAs from all 14 participants following primary immunization. The kinetics of the germinal centre response varied among participants, but S-binding germinal centre B cell frequencies increased at least transiently in all participants after boosting and persisted at high frequency in most individuals for at least 7 weeks. Notably, S-binding germinal centre B cells remained at or near their peak frequency 15 weeks after immunization in 8 of the 10 participants sampled at that time point, and these prolonged germinal centre responses had high proportions of S-binding cells (Fig. 2c–e, Extended Data Fig. 2b).

To evaluate the domains targeted by the S-protein-specific germinal centre response after vaccination, we generated recombinant monoclonal antibodies from single-cell-sorted S-binding germinal centre B cells (defined by the surface-marker phenotype CD19⁺CD3⁻IgD^{low}CD20^{high}CD38^{int}CD71⁺CXCR5⁺ lymphocytes) from three of the participants one week after boosting (Extended Data Fig. 2a). Fifteen, five and seventeen S-binding, clonally distinct monoclonal antibodies were generated from participants 07, 20 (lymph node 1) and 22, respectively (Extended Data Table 4). Of the 37 S-binding monoclonal antibodies, 17 bound the RBD, 6 recognized the N-terminal domain and 3 were cross-reactive with S proteins from seasonal betacoronavirus OC43; 2 of these monoclonal antibodies also bound S from seasonal betacoronavirus HKU1 (Fig. 3a). Clonal relatives of 14 out of 15, 1 out of 5 and 12 out of 17 of the S-binding monoclonal antibodies were identified among bulk-sorted total plasmablasts from PBMCs and germinal centre B cells at 4 weeks after immunization from participants 07, 20 and 22, respectively (Fig. 3b, Extended Data Figs. 2c, 3a, b, Extended Data Tables 5, 6). Clones related to S-binding monoclonal antibodies had significantly increased mutation frequencies in their immunoglobulin heavy chain variable region (*IGHV*) genes compared to previously published naive B cells¹⁹, particularly those related to monoclonal antibodies that cross-reacted with seasonal betacoronaviruses (Fig. 3c, d).

In addition to germinal centre B cells, we detected robust plasmablast responses in the draining lymph nodes of all 14 participants in the FNA cohort. S-binding plasmablasts (defined as CD19⁺CD3⁻IgD^{low}CD20^{low}CD38⁺CD71⁺BLIMP1⁺ lymphocytes) were detected in all of the lymph nodes that we sampled, and increased in frequency after boosting (Extended Data Fig. 4a, b). The detected plasmablasts were unlikely to be a contaminant of blood, because CD14⁺ monocyte and/or granulocyte frequencies were below 1% in all FNA samples (well below the 10% threshold that was previously established¹⁹) (Extended Data Table 3). Moreover, S-binding plasmablasts were detected in FNA samples at 5, 7 and 15 weeks after immunization, when they had become undetectable in blood from all participants in the cohort. The vast majority of S-binding lymph node plasmablasts were isotype-switched at 4 weeks after primary immunization, and IgA-switched cells accounted for 25% or more of the plasmablasts in 6 out of 14 participants (Extended Data Fig. 4c, d).

This study evaluated whether SARS-CoV-2 mRNA-based vaccines induce antigen-specific plasmablast and germinal centre B cell responses in humans. The vaccine induced a strong IgG-dominated plasmablast response in blood that peaked one week after the booster immunization. In the draining lymph nodes, we detected robust SARS-CoV-2 S-binding germinal centre B cell and plasmablast responses in aspirates from all 14 of the participants. These responses were detectable after the first immunization but greatly expanded after the booster injection. Notably, S-binding germinal centre B cells and plasmablasts persisted for at least 15 weeks after the first immunization (12 weeks after secondary immunization) in 8 of the 10 participants who were sampled at that time point. These responses to mRNA vaccination are superior to those seen after seasonal influenza virus vaccination in humans¹⁹, in whom haemagglutinin-binding germinal centre B cells were detected in only three out of eight participants. More robust germinal centre responses are consistent with antigen dissemination to multiple lymph nodes and the self-adjuvating characteristics of the mRNA–lipid nanoparticle vaccine platform compared to nonadjuvanted inactivated vaccines used for seasonal influenza virus vaccination^{7,20,21}. Our data in humans corroborate reports that demonstrate the induction of potent germinal centre responses by SARS-CoV-2 mRNA-based vaccines in mice^{22,23}.

To our knowledge, this is the first study to provide direct evidence for the induction of a persistent antigen-specific germinal centre B cell response after vaccination in humans. Dynamics of germinal centre B cell responses vary widely depending on the model system in which they are studied, although the most active period of the response usually occurs over the course of a few weeks. Primary alum-adjuvanted protein immunization of mice typically leads to germinal centre responses that peak 1–2 weeks after immunization and contract at least 10-fold within 5–7 weeks^{24–26}. Germinal centre responses induced by immunization with more robust adjuvants such as sheep red blood cells, complete Freund's adjuvant or saponin-based adjuvants tend to peak slightly later, at 2–4 weeks after vaccination, and can persist at low frequencies for several months^{27–33}. Although studies of extended durability are rare, antigen-specific germinal centre B cells have been found to persist for at least one year, albeit at very low levels^{28,30}. In this study, we show SARS-CoV-2 mRNA vaccine-induced germinal centre B cells are maintained at or near peak frequencies for at least 12 weeks after secondary immunization.

The persistence of S-binding germinal centre B cells and plasmablasts in draining lymph nodes is a positive indicator for induction of long-lived plasma cell responses²⁵. Future studies will be needed to examine whether mRNA vaccination induces a robust S-specific long-lived plasma cell compartment in the bone marrow. As part of such studies, it will be critical to generate a comprehensive set of monoclonal antibodies derived from plasmablasts and germinal centre B cells isolated from several time points to define the breadth of the B cell response elicited by this vaccine. None of the 14 participants in our study who underwent FNA of draining lymph nodes had a history of SARS-CoV-2 infection. Thus, further comparison of vaccine-induced germinal centre responses from naive and previously infected individuals will be informative. Finally, the work presented here focuses on the B cell component of the germinal centre reaction. A robust T follicular helper response sustains the germinal centre reaction^{34,35}. As such, studies are planned to investigate the magnitude, specificity and durability of the T follicular helper cell response after SARS-CoV-2 mRNA vaccination in humans.

A preliminary observation from our study is the dominance of RBD-targeting clones among responding germinal centre B cells. A more detailed analysis³⁶ of these RBD-binding monoclonal antibodies assessed their in vitro inhibitory capacity against the WA1/2020 D614G strain using an authentic SARS-CoV-2 neutralization assay: five showed high neutralization potency, with 80% neutralization values of less than 100 ng ml⁻¹. For the most part, RBD-binding clones contained few (<3) nonsynonymous nucleotide substitutions in their *IGHV* genes, which indicates that they originated from recently engaged naive B cells. This contrasts with the three cross-reactive germinal centre B cell clones that recognized conserved epitopes within the S proteins of betacoronaviruses. These cross-reactive clones had significantly higher mutation frequencies, which suggests a memory B cell origin. These data are consistent with previous findings from seasonal influenza virus vaccination in humans that show that the germinal centre reaction can engage pre-existing memory B cells directed against conserved epitopes as well as naive clones targeting novel epitopes¹⁹. However, these cross-reactive clones were not identified in all individuals and comprised a small fraction of responding B cells, consistent with a similar analysis of SARS-CoV-2 mRNA vaccine-induced plasmablasts³⁷. Overall, our data demonstrate the capacity of SARS-CoV-2 mRNA-based vaccines to induce robust and prolonged germinal centre reactions. The induced germinal centre reaction recruited cross-reactive memory B cells as well as newly engaged clones that target unique epitopes within SARS-CoV-2 S protein. Elicitation of high affinity and durable protective antibody responses is a hallmark of a successful humoral immune response to vaccination. By inducing robust germinal centre reactions, SARS-CoV-2 mRNA-based vaccines are on track for achieving this outcome.

Methods

No statistical methods were used to predetermine sample size.

Sample collection, preparation, and storage

All studies were approved by the Institutional Review Board of Washington University in St Louis. Written consent was obtained from all participants. Forty-one healthy volunteers were enrolled, of whom 14 provided axillary lymph node samples (Extended Data Table 1). In 5 of the 14 participants, a second draining lymph node was identified and sampled following secondary immunization. One participant (15) received the second immunization in the contralateral arm; draining lymph nodes were identified and sampled on both sides. Blood samples were collected in EDTA tubes, and PBMCs were enriched by density gradient centrifugation over Ficoll 1077 (GE) or Lymphopure (BioLegend). The residual red blood cells were lysed with ammonium chloride lysis buffer, and cells were immediately used or cryopreserved in 10% dimethylsulfoxide in fetal bovine serum (FBS). Ultrasound-guided FNA of axillary lymph nodes was performed by a radiologist or a qualified physician's assistant under the supervision of a radiologist. Lymph node dimensions and cortical thickness were measured, and the presence and degree of cortical vascularity and location of the lymph node relative to the axillary vein were determined before each FNA. For each FNA sample, six passes were made under continuous real-time ultrasound guidance using 25-gauge needles, each of which was flushed with 3 ml of RPMI 1640 supplemented with 10% FBS and 100 U ml⁻¹ penicillin–streptomycin, followed by three 1-ml rinses. Red blood cells were lysed with ammonium chloride buffer (Lonza), washed with phosphate-buffered saline (PBS) supplemented with 2% FBS and 2 mM EDTA, and immediately used or cryopreserved in 10% dimethylsulfoxide in FBS. Participants reported no adverse effects from phlebotomies or serial FNAs.

Cell lines

Expi293F cells were cultured in Expi293 Expression Medium (Gibco). Vero E6 (CRL-1586, American Type Culture Collection), Vero cells expressing TMPRSS2 (Vero-TMPRSS2 cells)³⁸ (a gift from S. Ding), and Vero cells expressing human ACE2 and TMPRSS2 (Vero-hACE2-TMPRSS2) (a gift of A. Creanga and B. Graham) cells were cultured at 37°C in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% FBS, 10 mM HEPES (pH 7.3), 1 mM sodium pyruvate, 1× nonessential amino acids and 100 U ml⁻¹ of penicillin–streptomycin. Vero-TMPRSS2 cell cultures were supplemented with 5 µg ml⁻¹ of blasticidin. Vero-hACE2-TMPRSS2 cell cultures were supplemented with 10 µg ml⁻¹ of puromycin.

Viruses

The 2019n-CoV/USA_WA1/2020 isolate of SARS-CoV-2 was obtained from the US Centers for Disease Control. The B.1.1.7 isolate from the UK was obtained from an infected individual. The point mutation D614G in the *S* gene was introduced into an infectious complementary DNA clone of the 2019n-CoV/USA_WA1/2020 strain as previously described³⁹. Nucleotide substitutions were introduced into a subclone puc57-CoV-2-F5-7 containing the *S* gene of the SARS-CoV-2 wild-type infectious clone⁴⁰. The *S* gene of the B.1.351 variant (first identified in South Africa) was produced synthetically by Gibson assembly. The full-length infectious cDNA clones of the variant SARS-CoV-2 viruses were assembled by in vitro ligation of seven contiguous cDNA fragments following a previously

described protocol⁴⁰. In vitro transcription was then performed to synthesize full-length genomic RNA. To recover the mutant viruses, the RNA transcripts were electroporated into Vero E6 cells. The viruses from the supernatant of cells were collected 40 h later and served as p0 stocks. All viruses were passaged once in Vero-hACE2-TMPRSS2 cells and subjected to deep sequencing after RNA extraction to confirm the introduction and stability of substitutions¹⁷. All virus preparation and experiments were performed in an approved biosafety level 3 facility.

Antigens

Recombinant soluble SARS-CoV-2 S protein, recombinant RBD of S, human coronavirus OC43 S, and human coronavirus HKU1 S were expressed as previously described⁴¹. In brief, mammalian cell codon-optimized nucleotide sequences coding for the soluble ectodomain of the S protein of SARS-CoV-2 (GenBank: MN908947.3, amino acids 1–1213) including a C-terminal thrombin cleavage site, T4 foldon trimerization domain and hexahistidine tag, and for the RBD (amino acids 319–541) along with the signal peptide (amino acids 1–14) plus a hexahistidine tag were cloned into mammalian expression vector pCAGGS. The S protein sequence was modified to remove the polybasic cleavage site (RRAR to A), and two pre-fusion stabilizing proline mutations were introduced (K986P and V987P, wild-type numbering). Expression plasmids encoding for the S of common human coronaviruses OC43 and HKU1 were provided by B. Graham⁴². Recombinant proteins were produced in Expi293F cells (ThermoFisher) by transfection with purified DNA using the ExpiFectamine 293 Transfection Kit (ThermoFisher). Supernatants from transfected cells were collected 3 days after transfection, and recombinant proteins were purified using Ni-NTA agarose (ThermoFisher), then buffer-exchanged into PBS and concentrated using Amicon Ultracel centrifugal filters (EMD Millipore). For flow cytometry staining, recombinant S was labelled with Alexa Fluor 647–NHS ester or biotinylated using the EZ-Link Micro NHS-PEG4-Biotinylation Kit (Thermo Fisher); excess Alexa Fluor 647 and biotin were removed using 7-kDa Zeba desalting columns (Pierce).

ELISpot assay

Plates were coated with Flucelvax Quadrivalent 2019/2020 seasonal influenza virus vaccine (Sequris), S or RBD. A direct ex vivo ELISpot assay was performed to determine the number of total, vaccine-binding or recombinant S-binding IgG- and IgA-secreting cells present in PBMC samples using IgG/IgA double-colour ELISpot Kits (Cellular Technology) according to the manufacturer's instructions. ELISpot plates were analysed using an ELISpot counter (Cellular Technology).

ELISAs

Assays were performed in 96-well plates (MaxiSorp; Thermo) coated with 100 μ l of recombinant S, RBD, N-terminal domain of S (SinoBiological), OC43 S, HKU1 S or bovine serum albumin diluted to 1 μ g ml⁻¹ in PBS, and plates were incubated at 4 °C overnight. Plates then were blocked with 10% FBS and 0.05% Tween 20 in PBS. Plasma or purified monoclonal antibodies were serially diluted in blocking buffer and added to the plates. Plates were incubated for 90 min at room temperature and then washed 3 times with 0.05% Tween 20 in PBS. Goat anti-human IgG-HRP (goat polyclonal, Jackson ImmunoResearch,

1:2,500), IgA (goat polyclonal, Jackson ImmunoResearch, 1:2,500) or IgM (goat polyclonal, Caltag, 1:4,000) were diluted in blocking buffer before adding to wells and incubating for 60 min at room temperature. Plates were washed 3 times with 0.05% Tween 20 in PBS and 3 times with PBS before the addition of *o*-phenylenediamine dihydrochloride peroxidase substrate (Sigma-Aldrich). Reactions were stopped by the addition of 1 M hydrochloric acid. Optical density measurements were taken at 490 nm. The area under the curve for each monoclonal antibody and half-maximal binding dilution for each plasma sample were calculated using Graphpad Prism v.8.

Focus reduction neutralization test

Plasma samples were dectotted by diluting 1:10 in DMEM supplemented with 2% FBS, 10 mM HEPES and 100 U ml⁻¹ penicillin–streptomycin and incubating for 3 h at 37 °C. Serial dilutions of resulting serum were incubated with 10² focus-forming units of different strains or variants of SARS-CoV-2 for 1 h at 37 °C. Antibody–virus complexes were added to Vero-TMPRSS2 cell monolayers in 96-well plates and incubated at 37 °C for 1 h. Subsequently, cells were overlaid with 1% (w/v) methylcellulose in MEM supplemented with 2% FBS. Plates were collected 30 h later by removing overlays and fixed with 4% PFA in PBS for 20 min at room temperature. Plates were washed and sequentially incubated with an oligoclonal pool of mouse anti-S monoclonal antibodies (SARS2-2, SARS2-11, SARS2-16, SARS2-31, SARS2-38, SARS2-57 and SARS2-71) (ref. ⁴³) and HRP-conjugated goat anti-mouse IgG (polyclonal, Sigma, 1:500) in PBS supplemented with 0.1% saponin and 0.1% bovine serum albumin. SARS-CoV-2-infected cell foci were visualized using TrueBlue peroxidase substrate (KPL) and quantified on an ImmunoSpot microanalyser (Cellular Technology).

Flow cytometry and cell sorting

Staining for flow cytometry analysis and sorting was performed using freshly isolated or cryo-preserved FNA, PBMC or tonsil samples. For analysis, cells were incubated for 30 min on ice with biotinylated and Alexa Fluor 647 conjugated recombinant soluble S and PD-1-BB515 (EH12.1, BD Horizon, 1:100) in 2% FBS and 2 mM EDTA in PBS (P2), washed twice, then stained for 30 min on ice with IgG–BV480 (goat polyclonal, Jackson ImmunoResearch, 1:100), IgA–FITC (M24A, Millipore, 1:500), CD45–A532 (HI30, Thermo, 1:50), CD38–BB700 (HIT2, BD Horizon, 1:500), CD20–Pacific Blue (2H7, 1:400), CD27–BV510 (O323, 1:50), CD8–BV570 (RPA-T8, 1:200), IgM–BV605 (MHM-88, 1:100), HLA-DR–BV650 (L243, 1:100), CD19–BV750 (HIB19, 1:100), CXCR5–PE–Dazzle 594 (J252D4, 1:50), IgD–PE–Cy5 (IA6-2, 1:200), CD14–PerCP (HCD14, 1:50), CD71–PE–Cy7 (CY1G4, 1:400), CD4–Spark685 (SK3, 1:200), streptavidin–APC–Fire750, CD3–APC–Fire810 (SK7, 1:50) and Zombie NIR (all BioLegend) diluted in Brilliant Staining buffer (BD Horizon). Cells were washed twice with P2, fixed for 1 h at 25 °C using the True Nuclear fixation kit (BioLegend), washed twice with True Nuclear Permeabilization/Wash buffer, stained with FOXP3–BV421 (206D, BioLegend, 1:15), Ki-67–BV711 (Ki-67, BioLegend, 1:200), Tbet–BV785 (4B10, BioLegend, 1:400), BCL6–PE (K112-91, BD Pharmingen, 1:25), and BLIMP1–A700 (646702, R&D, 1:50) for 1 h at 25 °C, washed twice with True Nuclear Permeabilization/Wash buffer, and acquired on an Aurora using SpectroFlo v.2.2 (Cytex). Flow cytometry data were analysed using FlowJo v.10 (Treestar).

For sorting germinal centre B cells, FNA single-cell suspensions were stained for 30 min on ice with CD19–BV421 (HIB19, 1:100), CD3–FITC (HIT3a, 1:200), IgD–PerCP–Cy5.5 (IA6-2, 1:200), CD71–PE (CY1G4, 1:400), CXCR5–PE–Dazzle 594 (J252D4, 1:50), CD38–PE–Cy7 (HIT2, 1:200), CD20–APC–Fire750 (2H7, 1:100), Zombie Aqua (all BioLegend), and Alexa Fluor 647 conjugated recombinant soluble S. For sorting plasmablasts, PBMCs were stained for 30 min on ice with CD20–PB (2H7, 1:400), CD71–FITC (CY1G4, 1:200), CD4–PerCP (OKT4, 1:100), IgD–PE (IA6-2, 1:200), CD38–PE–Cy7 (HIT2, 1:200), CD19–APC (HIB19, 1:200) and Zombie Aqua (all BioLegend). Cells were washed twice, and single S-binding germinal centre B cells (live singlet CD3⁺CD19⁺IgD^{low}CD20^{high}CD38^{int}CD71⁺CXCR5⁺S⁺) were sorted using a FACS Aria II into 96-well plates containing 2 µl Lysis Buffer (Clontech) supplemented with 1 U µl⁻¹ RNase inhibitor (NEB), or total germinal centre B cells or plasmablasts (live singlet CD3⁺CD19⁺IgD^{low}CD20^{low}CD38⁺CD71⁺) were bulk-sorted into buffer RLT Plus (Qiagen) and immediately frozen on dry ice.

Monoclonal antibody generation

Antibodies were cloned as previously described⁴⁴. In brief, VH, Vκ and Vλ genes were amplified by reverse transcription PCR and nested PCR reactions from singly sorted germinal centre B cells using primer combinations specific for IgG, IgM, IgA, Igκ and Igλ from previously described primer sets⁴⁵, and then sequenced. To generate recombinant antibodies, restriction sites were incorporated via PCR with primers to the corresponding heavy and light chain V and J genes. The amplified VH, Vκ and Vλ genes were cloned into IgG1 and Igκ or Igλ expression vectors, respectively, as previously described^{45–47}. Heavy and light chain plasmids were co-transfected into Expi293F cells (Gibco) for expression, and antibody was purified using protein A agarose chromatography (Goldbio). Sequences were obtained from PCR reaction products and annotated using the ImMunoGeneTics (IMGT)/V-QUEST database (http://www.imgt.org/IMGT_vquest/)^{48,49}. Mutation frequency was calculated by counting the number of nonsynonymous nucleotide mismatches from the germline sequence in the heavy chain variable segment leading up to the CDR3, while excluding the 5′ primer sequences that could be error-prone.

Bulk B cell receptor sequencing

RNA was purified from sorted plasmablasts from PBMCs and germinal centre B cells from lymph nodes from participants 07, 20 (lymph node 1) and 22 using the RNeasy Plus Micro kit (Qiagen). Reverse transcription, unique molecular identifier (UMI) barcoding, cDNA amplification, and Illumina linker addition to B cell heavy chain transcripts were performed using the human NEBNext Immune Sequencing Kit (New England Biolabs) according to the manufacturer's instructions. High-throughput 2× 300-bp paired-end sequencing was performed on the Illumina MiSeq platform with a 30% PhiX spike-in according to manufacturer's recommendations, except for performing 325 cycles for read 1 and 275 cycles for read 2.

Processing of B cell receptor bulk-sequencing reads

Demultiplexed pair-end reads were BLAST⁵⁰ed using blastn v.2.11.0 (ref. ⁵⁰) for PhiX removal and subsequently preprocessed using pRESTO v.0.6.2 (ref. ⁵¹) as follows. (1)

Reads with a mean Phred quality score below 20 were filtered. (2) Reads were aligned against template switch sequences and constant region primers (Extended Data Table 5), with a maximum mismatch rate of 0.5 and 0.2 respectively. (3) A UMI was assigned to each read by extracting the first 17 nucleotides preceding the template switch site. (4) Sequencing and multiplexing errors in the UMI region were then corrected using a previously published approach⁵². In brief, reads with similar UMIs were clustered using *cd-hit-est* v.4.8.1 (ref. ⁵³) on the basis of the pairwise distance of their UMIs with a similarity threshold of 0.83 that was estimated from 10,000 reads. The UMI-based read groups were further clustered within themselves on the basis of the pairwise distance of the non-UMI region of their reads with a similarity threshold of 0.8. Read clusters spanning multiple multiplexed samples were assigned to the majority sample. (5) Separate consensus sequences for the forward and reverse reads within each read cluster were constructed with a maximum error score of 0.1 and minimum constant region primer frequency of 0.6. If multiple constant region primers were associated with a particular read cluster, the majority primer was used. (6) Forward and reverse consensus sequence pairs were assembled by first attempting de novo assembly with a minimum overlap of 8 nucleotides and a maximum mismatch rate of 0.3. If unsuccessful, this was followed by reference-guided assembly using *blastn* v.2.11.0 (ref. ⁵⁰) with a minimum identity of 0.5 and an *E*-value threshold of 1×10^{-5} . (7) Isotypes were assigned by local alignment of the 3' end of each consensus sequence to isotype-specific internal constant region sequences (Extended Data Table 5) with a maximum mismatch rate of 0.3. Sequences with inconsistent isotype assignment and constant region primer alignment were removed. (8) Duplicate consensus sequences, except those with different isotype assignments, were collapsed into unique sequences. Only unique consensus sequences with at least two contributing reads were used subsequently (Extended Data Table 6).

B cell receptor genotyping

Initial germline V(D)J gene annotation was performed using *IgBLAST* v.1.17.1 (ref. ⁵⁴) with *IMGT/GENE-DB* release 202113-2 (ref. ⁵⁵). *IgBLAST* output was parsed using *Change-O* v.1.0.2 (ref. ⁵⁶). Quality control was performed, requiring each sequence to have non-empty V and J gene annotations; exhibit chain consistency in all annotations; bear fewer than 10 non-informative (non-A/T/G/C, such as N or -) positions; and carry a CDR3 with no N and a nucleotide length that is a multiple of 3. Individualized genotypes were inferred using *TIgGER* v.1.0.0 (ref. ⁵⁷) and used to finalize V(D)J annotations. Sequences annotated as non-productively rearranged by *IgBLAST* were removed from further analysis.

Clonal lineage analysis


B cell clonal lineages were inferred on the basis of productively rearranged heavy chain sequences using hierarchical clustering with single linkage^{58,59}. Sequences were first partitioned based on common V and J gene annotations and CDR3 lengths. Within each partition, sequences with CDR3s that were within 0.15 normalized Hamming distance from each other were clustered as clones. This distance threshold was determined by manual inspection in conjunction with kernel density estimates to identify the local minimum between the two modes of the within-participant bimodal distance-to-nearest distribution (Extended Data Fig. 3a). Following clonal clustering, full-length clonal consensus germline

sequences were reconstructed for each clone with D-segment and N/P regions masked with Ns, resolving any ambiguous gene assignments by majority rule. Within each clone, duplicate IMGT-aligned V(D)J sequences from bulk sequencing were collapsed with the exception of duplicates derived from different B cell compartments or isotypes. Clones were visualized as networks⁶⁰ using igraph v.1.2.5 (ref. ⁶¹). First, a full network was calculated for each clone, in which an edge was drawn between every pair of sequences with CDR3s that were within 0.15 normalized Hamming distance from each other. Then, a minimum spanning tree was derived from the full network, in which only edges essential for ensuring that all sequences connected in the full network remain connected in the minimum spanning tree either directly or indirectly were retained. The minimum spanning tree was then visualized for each clone.

Calculation of somatic hypermutation frequency


Mutation frequency was calculated by counting the number of nucleotide mismatches from the germline sequence in the observed heavy chain variable segment leading up to the CDR3, while excluding the first 18 positions that could be error-prone owing to the primers used for generating the monoclonal antibody sequences. Calculation was performed using the calcObservedMutations function from SHazaM v.1.0.2 (ref. ⁵⁶).

Extended Data




Extended Data Fig. 1|. Antibody response to SARS-CoV-2 immunization.

a, Plasma IgA (left) and IgM (right) titres against SARS-CoV-2 S measured by ELISA in participants without (red) and with (black) a history of SARS-CoV-2 infection at baseline, and 3, 4, 5, 7 and 15 weeks after immunization. **b**, Neutralizing activity of serum against WA1/2020 D614G (left), B.1.1.7 (middle) and a chimeric virus expressing B.1.351 S (right) in Vero-TMPRSS2 cells at baseline, 3, and 5 or 7 weeks after immunization in participants without (red) and with (black) a history of SARS-CoV-2 infection. *P* values from two-sided Mann-Whitney tests. Dotted lines indicate limits of detection. Horizontal lines indicate the geometric mean. Symbols at each time point represent one sample ($n = 41$). Results are from one experiment performed in duplicate.



Extended Data Fig. 2]. Gating strategies for analysis of germinal centre response to SARS-CoV-2 immunization.


a, c, Sorting gating strategies for S-binding germinal centre B cells from FNAs (**a**) and total plasmablasts from PBMCs (**c**). **b**, Representative plot of germinal centre B cells in tonsil.



Extended Data Fig. 3|. Clonal analysis of germinal centre response to SARS-CoV-2 immunization.

a, Distance-to-nearest-neighbour plots for choosing a distance threshold for inferring clones via hierarchical clustering. After partitioning sequences based on common V and J genes and CDR3 length, the nucleotide Hamming distance of a CDR3 to its nearest nonidentical neighbour from the same participant within its partition was calculated and normalized by CDR3 length (blue histogram). For reference, the distance to the nearest nonidentical neighbour from other participants was calculated (green histogram). A clustering threshold of 0.15 (dashed black line) was chosen via manual inspection and kernel density estimate (dashed purple line) to separate the two modes of the within-participant distance distribution representing, respectively, sequences that were probably clonally related and unrelated.

b, Clonal relationship of sequences from S-binding germinal centre-derived monoclonal antibodies (cyan) to sequences from bulk repertoire analysis of plasmablasts sorted from PBMCs (red) and germinal centre B cells (blue) 4 weeks after immunization. Each clone is visualized as a network in which each node represents a sequence and sequences are linked as a minimum spanning tree of the network. Symbol shape indicates sequence isotype: IgG (circle), IgA (star) and IgM (square); symbol size corresponds to sequence count.



Extended Data Fig. 4|. Lymph node plasmablast response to SARS-CoV-2 immunization.

a, c, Representative flow cytometry plots showing gating of $CD20^{low}CD38^{+}$ $CD71^{+}BLIMP1^{+}S^{+}$ plasmablasts from $IgD^{low}CD19^{+}CD3^{-}$ live singlet lymphocytes (**a**) and IgA and IgM staining on S^{+} plasmablasts (**c**) in FNA samples. **b,** Kinetics of S^{+} plasmablasts gated as in **a** from FNA of draining lymph nodes. Symbols at each time point represent one FNA sample; square symbols denote second lymph node sampled ($n = 14$). Horizontal lines indicate the median. **d,** Percentages of IgM^{+} (teal), IgA^{+} (yellow) or $IgM^{-}IgA^{-}$ (purple) S^{+} plasmablasts gated as in **c** in FNA of draining lymph nodes 4 weeks after primary immunization. Each bar represents one sample ($n = 14$).

Extended Data Table 1|

Participant demographics

Variable	Total N=41 N (%)	Lymph node N=14 N (%)
Age (median [range])	37 (28-73)	37 (28-52)
Sex		
Female	18 (43.9)	8 (57.1)
Male	23 (56.1)	6 (42.9)
Race		
White	30 (73.2)	11 (78.6)
Asian	9 (22)	2 (14.3)
Black	1 (2.4)	1 (7.1)
Other	1 (2.4)	0 (0)
Ethnicity		
Not of Hispanic, Latinx, or Spanish origin	39 (95.1)	13 (92.9)
Hispanic, Latinx, Spanish origin	2 (4.9)	1 (7.1)
BMI (median [range])	25.4 (21.4-40)	23.9 (21.4-40)

Variable	Total N=41 N (%)	Lymph node N=14 N (%)
Comorbidities		
Lung disease	2 (4.9)	1 (7.1)
Diabetes mellitus	0 (0)	0 (0)
Hypertension	7 (17.1)	2 (14.3)
Cardiovascular	0 (0)	0 (0)
Liver disease	0 (0)	0 (0)
Chronic kidney disease	0 (0)	0 (0)
Cancer on chemotherapy	0 (0)	0 (0)
Hematological malignancy	0 (0)	0 (0)
Pregnancy	0 (0)	0 (0)
Neurological	0 (0)	0 (0)
HIV	0 (0)	0 (0)
Solid organ transplant recipient	0 (0)	0 (0)
Bone marrow transplant recipient	0 (0)	0 (0)
Hyperlipidemia	1 (2.4)	0 (0)
Confirmed SARS-CoV-2 infection	8 (19.5)	0 (0)
Time from SARS-CoV-2 infection to baseline visit in days (median [range])	122 (50-307)	--

Extended Data Table 2]

Vaccine side effects

Variable	Total N=41 N (%)	Total N=41 N (%)	
First dose		Second dose	
None	3 (7.3)	None	1 (2.4)
Chills	5 (12.2)	Chills	15 (36.6)
Fever	2 (4.9)	Fever	6 (14.6)
Headache	6 (14.6)	Headache	11 (26.8)
Injection site pain	33 (80.5)	Injection site pain	36 (87.8)
Muscle or joint pain	9 (21.9)	Muscle or joint pain	32 (78)
Fatigue	8 (19.5)	Fatigue	23 (56.1)
Sweating	0 (0)	Sweating	2 (4.8)
Duration of side effects in hours (median [range])			
Chills	48 (6-72)	Chills	24 (4-48)
Fever	9 (6-12)	Fever	24 (1-48)
Headache	9 (3-48)	Headache	24 (4-48)
Injection site pain	36 (2-120)	Injection site pain	36 (2-120)
Muscle or joint pain	36 (1-48)	Muscle or joint pain	24 (1-48)
Fatigue	30 (3-48)	Fatigue	24 (3-144)
Sweating	0 (0)	Sweating	18 (18)

Extended Data Table 3

Lymph node population frequencies

Participant	Week post immunization	LN #	Total GC (%CD19)	S+ GC (%CD19)	S+ PB (%CD19)	CD14 (%live singlet)
01	3	1	15.1744	3.2617	0.0718	0.2134
01	4	1	13.7195	5.4700	0.8436	0.0588
01	5	1	11.1280	4.0445	1.1611	0.1461
01	7	1	31.1819	13.5866	1.6436	0.1469
01	15	1	29.0930	18.1334	2.0446	0.1628
02	3	1	8.2782	1.3827	0.0132	0.1590
02	4	1	34.1504	9.7890	0.2102	0.1705
02	4	2	14.0743	4.7121	0.2521	0.1371
02	5	1	44.6608	11.6465	0.4086	0.0743
02	5	2	13.5353	3.8936	0.2893	0.1361
02	7	1	21.8959	6.0492	0.3725	0.2486
02	7	2	23.1123	9.3883	0.5557	0.7063
02	15	1	7.1063	0.0197	0.0020	0.1649
04	3	1	4.6727	0.5706	0.0538	0.1934
04	4	1	13.9308	2.8621	0.0885	0.3733
04	5	1	11.3856	5.9721	0.4296	0.7237
04	7	1	43.8266	6.4556	0.2019	0.1436
04	15	1	3.7193	0.7127	0.0025	0.9901
07	3	1	21.0403	4.6411	0.0697	0.1927
07	4	1	19.6634	4.9771	0.2599	0.1507
07	5	1	11.3504	3.8557	0.2576	0.4177
07	7	1	39.2049	14.7032	0.6765	0.6582
07	15	1	28.9957	20.1221	0.3248	0.0349
08	3	1	9.9010	1.2181	0.0651	0.2738
08	4	1	1.3233	0.4150	0.0904	0.1670
08	5	1	3.9913	0.9238	0.1507	0.3377
08	7	1	12.1411	4.2393	0.7559	0.8097
10	3	1	7.7130	1.1146	0.0399	0.2216
10	4	1	5.9172	1.4892	0.3494	0.0676
10	4	2	5.7036	1.3733	0.1867	0.0860
10	5	1	2.8213	0.9125	0.3428	0.0772
10	5	2	3.4006	1.0486	0.4156	0.0517
10	7	1	7.3456	3.1376	0.8776	0.2061
10	7	2	4.2626	1.0628	0.1663	0.1314
10	15	1	19.2991	14.2480	1.0759	0.0340
10	15	2	7.0114	2.7615	0.1849	0.0292
13	3	1	14.8994	3.5681	0.0199	0.5633
13	4	1	8.5564	3.0085	0.2116	0.3352

Participant	Week post immunization	LN #	Total GC (%CD19)	S+ GC (%CD19)	S+ PB (%CD19)	CD14 (%live singlet)
13	5	1	7.1981	2.1647	0.3036	0.4254
13	7	1	15.9621	3.7382	0.6532	0.3253
13	15	1	20.1410	10.1032	0.4304	1.6315
15	3	1	13.0526	2.9882	0.0838	0.0715
15	4	1	26.8834	8.1055	0.1196	0.1948
15	4	2	0.3157	0.0169	0.1039	0.1379
15	5	1	44.5687	9.7412	0.3016	0.0786
15	5	2	0.6237	0.0247	0.0098	0.2388
16	3	1	5.1983	0.7456	0.0195	0.2619
16	4	1	7.6114	1.5173	0.0510	0.1431
16	4	2	1.2226	0.2419	0.0190	0.1142
16	5	1	17.0381	3.3806	0.1261	0.0570
16	5	2	7.4397	1.8530	0.1101	0.1405
20	3	1	0.4058	0.0257	0.0076	0.2140
20	4	1	7.4714	3.0853	0.0115	0.1478
20	4	2	7.8030	1.2875	0.0505	0.1149
20	5	1	2.0994	0.3146	0.0000	0.2934
20	5	2	3.3579	0.7320	0.0811	0.1607
20	7	1	0.5222	0.0378	0.0000	0.4082
20	7	2	13.6571	4.4611	0.2402	0.1100
20	15	1	0.4687	0.0391	0.0033	0.8360
20	15	2	16.9158	11.1431	0.4222	0.2930
21	4	1	20.1451	5.9981	0.3831	0.1274
21	7	1	14.4498	5.2617	1.7381	0.1088
22	3	1	24.7057	4.4770	0.0352	0.1818
22	4	1	20.6325	5.4021	0.1707	0.1613
22	5	1	19.6620	4.9759	0.3147	0.2005
22	7	1	25.8583	7.3746	0.7954	0.3576
22	15	1	22.0049	9.7484	0.8297	0.2798
28	3	1	6.3630	1.1301	0.0372	0.1303
28	4	1	6.2272	1.1718	0.1281	0.2226
28	15	1	12.7274	7.2239	1.1391	0.6584
43	3	1	29.0401	4.5319	0.0505	0.5172
43	4	1	29.3971	9.5485	0.6432	0.3236
43	5	1	26.0545	6.3729	0.5631	0.9658
43	7	1	29.4153	15.3730	2.4781	0.0902
43	15	1	35.1837	15.5455	0.9446	0.0106

Extended Data Table 4|

Immunoglobulin gene usage of S-binding monoclonal antibodies

Name	Native isotype	Heavy Chain				Gene usage	Nucleotide mutations*
		Gene usage	Nucleotide mutations*	AA mutations	HCDR3		
07.1A11	IgM	VH3-15 DH1-7 JH4	4/283=0.0141	4	TTGWFTGTYGDYFDY	VK1-33 JK4	1/267=0.0037
07.1A12	IgA1	VH3-49 D2-15 JH4	3/281=0.0107	3	TRVKYCSGGSCYGYHFDH	VK3-15 JK3	4/262=0/0.0153
07.1E10	IgG1	VH4-34 D6-19 JH6	5/272=0.0184	5	ARVVIAVAGTYPIQVYYYYGMDV	VK1-27 JK1	2/266=0.0075
07.1E11	IgA1	VH3-30 D3-22 JH6	1/278=0.0036	1	AKEEMIEDWGMDV	VL3-1 JL2	2/265=0.0075
07.1H09	IgG1	VH3-66 DH3-10 JH3	3/275=0.0109	3	ARDFREGAFDI	VK1-9 JK4	0/266=0
07.2A07	IgG1	VH3-21 DH2-21 JH4	6/277=0.0217	6	ARAGFVPKRAYCGGDCWYYFDY	VK3-11 JK4	0/263=0
07.2A08	IgG1	VH4-4 DH6-19 JH4	2/275=0.0073	2	ATDGGWYTFDH	VL3-1 JL2	3/265=0.0113
07.2A10	IgG1	VH4-31 DH3-16 JH3	1/278=0.0036	1	ARYPVWGAFDI	VK1-33 JK3	3/267=0.0112
07.2C08	IgG1	VH1-58 DH2-15 JH3	2/275=0.0073	2	AAAYCSGGSCSDGFDI	VK3-20 JK1	5/266=0.0188
07.2C12	IgG1	VH3-30-3 DH1-26 JH3	3/277=0.0108	3	ARARGGSYSGAFDI	VK3-20 JK2	1/267=0.0037
07.3D07	IgG1	VH3-30-3 DH5-18 JH4	3/277=0.0108	3	ARVLWLRGMFDY	VL6-57 JL3	2/278=0.0072
07.4A07	IgG1	VH3-30-3 DH3-10 JH4	3/277=0.0108	2	ARGDYYSYSGSYPGKTFDY	VK1-33 JK4	1/266=0.0038
07.4B05	IgG1	VH1-69 DH1-26 JH5	1/277=0.0036	1	ARGRLDSYSGSYYSWFDP	VK4-1 JK2	2/283=0.0071
07.4C10	IgG1	VH3-23 DH3-22 JH4	1/276=0.0036	1	AKNEMAMIVVVITLFDY	VL1-51 JL3	2/277=0.0072
07.4D09	IgG1	VH4-4 DH2-15 JH4	1/274=0.0036	1	ATKYCSGGSCSYFGY	VL2-23 JL3	0/277=0
20.1A12	IgG1	VH3-30 DH1-26 JH4	2/277=0.0072	2	AKGHSGSYRAPFDY	VK3-20 JK2	0/263=0
20.2A03	IgM	VH3-33 DH3-10 JH4	1/278=0.0036	1	AREAYFGSGSSPDY	VL3-10 JL2	2/272=0.0074

Name	Native isotype	Heavy Chain				Gene usage	Nucleotide mutations _%
		Gene usage	Nucleotide mutations _%	AA mutations	HCDR3		
20.3C08	IgG1	VH3-7 DH3-22 JH4	1/278=0.0036	1	AREGTYYYDSSAYYNGGLDY	VL3-10 JL2	2/268=0.0075
20.3D12	IgG1	VH3-33 DH1-1 JH4	7/278=0.0252	7	APEPVQLEPEVRLDY	VL3-10 JL1	1/272=0.0037
20.3F12	IgG1	VH3-7 DH4-11 JH4	0/278=0	0	ARDQGVTTGPFYD	VL3-1 JL2	1/265=0.0038
22.1A11	IgG3	VH3-30-3 DH3-16 JH4	0/278=0	0	ARDLVVWEELAGGY	VL3-10 JL3	2/270=0.0074
22.1B04	IgG1	VH3-30 DH2-15 JH4	4/279=0.0143	3	AKQGGGTYCGGSCYRGYFDY	VK1-33 JK4	2/266=0.0075
22.1B08	IgA1	VH1-46 DH4-17 JH3	16/278=0.0576	15	ARDPRPAVTNVNDAFDL	VK3-11 JK2	5/267=0.0187
22.1B12	IgG1	VH3-53 DH3-10 JH4	8/273=0.0293	5	ARSHLEVRGVFDN	VK4-1 JK2	1/282=0.0035
22.1C02	IgG1	VH3-20 DH7-27 JH4	5/275=0.0182	4	ARGTGAADY	VK3-20 JK2	6/266=0.0226
22.1E07	IgA1	VH3-33 DH4-17 JH4	3/278=0.0108	3	AREGVYGDIGGAGLDY	VL3-10 JL1	4/272=0.0147
22.1E11	IgG1	VH3-30 DH2-15 JH4	2/274=0.0073	2	AKMGGVYCSAGNCYSGRLEY	VK1-33 JK3	0/263=0
22.1G10	IgG1	VH4-59 DH2-21 JH5	12/275=0.0436	11	ARETVNNWVDP	VK4-1 JK1	10/282=0.0355
22.2A06	IgG3	VH5-51 DH3-3 JH4	1/277=0.0036	1	ARREWGGSLGHIDY	VL6-57 JL2	4/276=0.0145
22.2A08	IgG1	VH4-59 DH2-2 JH6	4/274=0.0146	4	ARGQGVPAALYGM DV	VL1-40 JL2	3/281=0.0107
22.2B06	IgM	VH3-53 DH1-1 JH6	2/275=0.0073	2	ARDLQLYGM DV	VL3-21 JL2	2/268=0.0075
22.2F03	IgM	VH1-18 DH6-13 JH6	1/277=0.0036	1	ARVPLVGYSSSWYDNEKNYYYYYYGM DV	VL3-25 JL1	1/270=0.0037
22.3A06	IgG1	VH3-23 DH5-18 JH5	2/277=0.0072	2	AKADTAMAWYNWFDP	VK3-11 JK4	3/264=0.0114
22.3A11	IgG1	VH4-34 DH7-27 JH2	1/270=0.0037	1	ARVWVRWYFDL	VL3-21 JL1	4/272=0.0147
22.3A12	IgG1	VH1-46 DH2-21 JH4	4/275=0.0145	4	ASSLPARGGVPGR LNY	VL1-51 JL2	3/277=0.0108
22.3D11	IgG1	VH5-51 D4-17 JH5	1/278=0.0036	1	ARHHLDDYD DYVGHWFDP	VL1-40 JL3	0/281=0

Name	Native isotype	Heavy Chain				Gene usage	Nucleotide mutations _‡
		Gene usage	Nucleotide mutations _‡	AA mutations	HCDR3		
22.3F08	IgG1	VH1-18 DH2-2 JH6	4/275=0.0145	4	ASCPRRPAAIGDYYGMDV	VL3-21 JL7	1/271=0.0037

*V-region nonsynonymous nucleotide substitutions

Extended Data Table 5]

Template switch sequences, constant region primers and isotype-specific internal constant region sequences for bulk BCR sequencing and processing

Template switch sequences	
TS-shift0	TACGGG
TS-shift1	ATACGGG
TS-shift2	TCTACGGG
TS-shift3	CGATACGGG
TS-shift4	GATCTACGGG
Constant region primers	
Human-IGHM	GAATTCTCACAGGAGACGAGG
Human-IGHD	TGTCTGCACCCTGATATGATGG
Human-IGHA	GGGTGCTGYMGAGGCTCAG
Human-IGHE	TTGCAGCAGCGGGTCAAGG
Human-IGHG	CCAGGGGGAAGACSGATG
Human-IGK	GACAGATGGTGCAGCCACAG
Human-IGL	AGGGYGGGAACAGAGTGAC
Isotype-specific internal constant region sequences	
Human-IGHA-InternalC	GGCTGGTCGGGGATGC
Human-IGHD-InternalC	GAGCCTTGGTGGGTGC
Human-IGHE-InternalC	GGCTCTGTGTGGAGGC
Human-IGHG-InternalC	GGCCCTTGGTGGARGC
Human-IGHM-InternalC	GGGCGGATGCACTCCC
Human-IGKC-IGKJ-InternalC	TTCGTTTRATHTCAS
Human-IGLC-1-InternalC	TGGGGTTGGCCTTGGG
Human-IGLC-2-InternalC	AGGGGGCAGCCTTGGG
Human-IGLC-3-InternalC	YRGCCTTGGGCTGACC
Human-IGLC-4-InternalC	GCTGCCAAACATGTGC

Extended Data Table 6]

Processing of bulk sequencing BCR reads

Participant	Sample	Cell Count	Sequence Count			
			Input	Preprocessed	Post-QC Productive Heavy Chains	Unique Heavy Chain VDJs
07	d28 blood plasmablast	8361	2307288	8294	6031	3014
20	d28 blood plasmablast	6136	2068139	2320	1453	951
22	d28 blood plasmablast	15496	1801330	16126	13733	6266
07	d28 lymph node germinal centre	25754	1104539	2429	1700	1211
22	d28 lymph node germinal centre	10236	2117620	552	364	268

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

We thank the donors for providing specimens, L. Kessels, A. J. Winingham, K. Safi and the staff of the Infectious Diseases Clinical Research Unit at Washington University School of Medicine for assistance with scheduling participants and sample collection, and E. Lantelme for facilitating sorting. The Vero-TMPRSS2 cells were provided by S. Ding. The expression plasmids encoding the S of coronaviruses OC43 and HKU1 were provided by K. Corbett and B. Graham. The laboratory of A.H.E. was supported by National Institute of Allergy and Infectious Diseases (NIAID) grants U01AI141990 and 1U01AI150747 and NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) contract HHSN272201400006C. The laboratories of A.H.E. and F.K. were supported by NIAID CEIRS contract HHSN272201400008C and NIAID Collaborative Influenza Vaccine Innovation Centers contract 75N93019C00051. The laboratory of M.S.D. was supported by R01 AI157155. The laboratory of P.Y.-S. was supported by NIH grants AI134907 and UL1TR001439, and awards from the Sealy & Smith Foundation, Kleberg Foundation, the John S. Dunn Foundation, the Amon G. Carter Foundation, the Gilson Longenbaugh Foundation and the Summerfield Robert Foundation. J.S.T. was supported by NIAID 5T32CA009547. J.B.C. was supported by a Helen Hay Whitney Foundation postdoctoral fellowship. The WU368 study was reviewed and approved by the Washington University Institutional Review Board (approval no. 202012081).

Competing interests

The laboratory of A.H.E. received funding under sponsored research agreements that are unrelated to the data presented in the current study from Emergent BioSolutions and from AbbVie. A.H.E. is a consultant for Mubadala Investment Company and the founder of ImmuneBio Consulting. J.S.T., A.J.S., M.S.D. and A.H.E. are recipients of a licensing agreement with Abbvie that is unrelated to the data presented in the current study. M.S.D. is a consultant for Inbios, Vir Biotechnology, Fortress Biotech and Carnival Corporation, and on the Scientific Advisory Boards of Moderna and Immunome. The laboratory of M.S.D. has received unrelated funding support in sponsored research agreements from Moderna, Vir Biotechnology and Emergent BioSolutions. A patent application related to this work has been filed by Washington University School of Medicine. The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which list F.K. as co-inventor. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2. F.K. has consulted for Merck and Pfizer (before 2020), and is currently consulting for Pfizer, Seqirus and Avimex. The Laboratory of F.K. is also collaborating with Pfizer on animal models of SARS-CoV-2. The laboratory of P.-Y.S. has received sponsored research agreements from Pfizer, Gilead, Merck and IGM Sciences Inc. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official view of NIAID or NIH.

Data availability

Antibody sequences are deposited on GenBank under the following accession numbers: MW926396–MW926407, MW926409–MW926430, MW926432–MW926441 and MZ292481–MZ292510, available from Gen-Bank/EMBL/DDBJ. Bulk sequencing reads are deposited on Sequence Read Archive under BioProject PRJNA731610. Processed B cell receptor data are deposited at <https://doi.org/10.5281/zenodo.5042252>. The IMGT/V-QUEST database is accessible at http://www.imgt.org/IMGT_vquest/. Other relevant data are available from the corresponding authors upon request.

References

1. Mulligan MJ et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. *Nature* 586, 589–593 (2020). [PubMed: 32785213]
2. Jackson LA et al. An mRNA vaccine against SARS-CoV-2 – preliminary report. *N. Engl. J. Med* 383, 1920–1931 (2020). [PubMed: 32663912]
3. Sahin U et al. COVID-19 vaccine BNT162b1 elicits human antibody and T_H1 T cell responses. *Nature* 586, 594–599 (2020). [PubMed: 32998157]
4. Polack FP et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. *N. Engl. J. Med* 383, 2603–2615 (2020). [PubMed: 33301246]
5. Baden LR et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. *N. Engl. J. Med* 384, 403–416 (2021). [PubMed: 33378609]
6. Zhou X et al. Self-replicating Semliki forest virus RNA as recombinant vaccine. *Vaccine* 12, 1510–1514 (1994). [PubMed: 7879415]
7. Cagigi A & Loré K Immune responses induced by mRNA vaccination in mice, monkeys and humans. *Vaccines* 9, 61 (2021). [PubMed: 33477534]
8. Karikó K et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. *Mol. Ther* 16, 1833–1840 (2008). [PubMed: 18797453]
9. Schlake T, Thess A, Fotin-Mleczek M & Kallen K-J Developing mRNA-vaccine technologies. *RNA Biol.* 9, 1319–1330 (2012). [PubMed: 23064118]
10. Graham BS, Mascola JR & Fauci AS Novel vaccine technologies: essential components of an adequate response to emerging viral diseases. *J. Am. Med. Assoc* 319, 1431–1432 (2018).
11. Bettini E & Locci M SARS-CoV-2 mRNA vaccines: immunological mechanism and beyond. *Vaccines* 9, 147 (2021). [PubMed: 33673048]
12. Amit S, Regev-Yochay G, Afek A, Kreiss Y & Leshem E Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients. *Lancet* 397, 875–877 (2021).
13. Dagan N et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. *N. Engl. J. Med* 384, 1412–1423 (2021). [PubMed: 33626250]
14. Vasileiou E et al. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. *Lancet* 397, 1646–1657 (2021). [PubMed: 33901420]
15. Case JB et al. Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2. *Cell Host Microbe* 28, 475–485.e5 (2020). [PubMed: 32735849]
16. Liu Y et al. Neutralizing activity of BNT162b2-elicited serum. *N. Engl. J. Med* 384, 1466–1468 (2021). [PubMed: 33684280]
17. Chen RE et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. *Nat. Med* 27, 717–726 (2021). [PubMed: 33664494]
18. Leung K, Shum MH, Leung GM, Lam TT & Wu JT Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020. *Euro Surveill.* 26, 2002106 (2021).

19. Turner JS et al. Human germinal centres engage memory and naive B cells after influenza vaccination. *Nature* 586, 127–132 (2020). [PubMed: 32866963]
20. Pardi N et al. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. *J. Control. Release* 217, 345–351 (2015). [PubMed: 26264835]
21. Liang F et al. Efficient targeting and activation of antigen-presenting cells in vivo after modified mRNA vaccine administration in rhesus macaques. *Mol. Ther* 25, 2635–2647 (2017). [PubMed: 28958578]
22. Tai W et al. A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2. *Cell Res.* 30, 932–935 (2020). [PubMed: 32759966]
23. Lederer K et al. SARS-CoV-2 mRNA vaccines foster potent antigen-specific germinal center responses associated with neutralizing antibody generation. *Immunity* 53, 1281–1295.e5 (2020). [PubMed: 33296685]
24. Kaji T et al. Distinct cellular pathways select germline-encoded and somatically mutated antibodies into immunological memory. *J. Exp. Med* 209, 2079–2097 (2012). [PubMed: 23027924]
25. Weisel FJ, Zuccarino-Catania GV, Chikina M & Shlomchik MJ A Temporal switch in the germinal center determines differential output of memory B and plasma cells. *Immunity* 44, 116–130 (2016). [PubMed: 26795247]
26. Good-Jacobson KL et al. Regulation of germinal center responses and B-cell memory by the chromatin modifier MOZ. *Proc. Natl Acad. Sci. USA* 111, 9585–9590 (2014). [PubMed: 24979783]
27. Bachmann MF, Odermatt B, Hengartner H & Zinkernagel RM Induction of long-lived germinal centers associated with persisting antigen after viral infection. *J. Exp. Med* 183, 2259–2269 (1996). [PubMed: 8642335]
28. Dogan I et al. Multiple layers of B cell memory with different effector functions. *Nat. Immunol* 10, 1292–1299 (2009). [PubMed: 19855380]
29. Rothausler K & Baumgarth N B-cell fate decisions following influenza virus infection. *Eur. J. Immunol* 40, 366–377 (2010). [PubMed: 19946883]
30. Pape KA, Taylor JJ, Maul RW, Gearhart PJ & Jenkins MK Different B cell populations mediate early and late memory during an endogenous immune response. *Science* 331, 1203–1207 (2011). [PubMed: 21310965]
31. Turner JS, Benet ZL & Grigorova I Transiently antigen primed B cells can generate multiple subsets of memory cells. *PLoS ONE* 12, e0183877 (2017). [PubMed: 28850584]
32. Havenar-Daughton C et al. Rapid germinal center and antibody responses in non-human primates after a single nanoparticle vaccine immunization. *Cell Rep.* 29, 1756–1766.e8 (2019). [PubMed: 31722194]
33. Cirelli KM et al. Slow delivery immunization enhances HIV neutralizing antibody and germinal center responses via modulation of immunodominance. *Cell* 177, 1153–1171.e28 (2019). [PubMed: 31080066]
34. Qi H, Cannons JL, Klauschen F, Schwartzberg PL & Germain RN SAP-controlled T-B cell interactions underlie germinal centre formation. *Nature* 455, 764–769 (2008). [PubMed: 18843362]
35. Johnston RJ et al. Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation. *Science* 325, 1006–1010 (2009). [PubMed: 19608860]
36. Schmitz AJ et al. A public vaccine-induced human antibody protects against SARS-CoV-2 and emerging variants. Preprint at 10.1101/2021.03.24.436864 (2021).
37. Amanat F et al. SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD and S2. *Cell* 10.1016/j.cell.2021.06.005 (2021)
38. Zang R et al. TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes. *Sci. Immunol* 5, eabc3582 (2020). [PubMed: 32404436]
39. Plante JA et al. Spike mutation D614G alters SARS-CoV-2 fitness. *Nature* 592, 116–121 (2021). [PubMed: 33106671]
40. Xie X et al. An infectious cDNA clone of SARS-CoV-2. *Cell Host Microbe* 27, 841–848.e3 (2020). [PubMed: 32289263]

41. Stadlbauer D et al. SARS-CoV-2 seroconversion in humans: a detailed protocol for a serological assay, antigen production, and test setup. *Curr. Protoc. Microbiol* 57, e100 (2020). [PubMed: 32302069]
42. Pallesen J et al. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. *Proc. Natl Acad. Sci. USA* 114, E7348–E7357 (2017). [PubMed: 28807998]
43. Liu Z et al. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. *Cell Host Microbe* 29, 477–488.e4 (2021). [PubMed: 33535027]
44. Wrarmert J et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. *J. Exp. Med* 208, 181–193 (2011). [PubMed: 21220454]
45. Smith K et al. Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. *Nat. Protoc* 4, 372–384 (2009). [PubMed: 19247287]
46. Wrarmert J et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. *Nature* 453, 667–671 (2008). [PubMed: 18449194]
47. Nachbagauer R et al. broadly reactive human monoclonal antibodies elicited following pandemic H1N1 influenza virus exposure protect mice against highly pathogenic H5N1 challenge. *J. Virol* 92, 1–17 (2018).
48. Brochet X, Lefranc M-P & Giudicelli V IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. *Nucleic Acids Res.* 36, W503–W508 (2008). [PubMed: 18503082]
49. Giudicelli V, Brochet X & Lefranc M-P IMGT/V-QUEST: IMGT standardized analysis of the immunoglobulin (IG) and T cell receptor (TR) nucleotide sequences. *Cold Spring Harb. Protoc* 2011, pdb.prot5633 (2011).
50. Camacho C et al. BLAST+: architecture and applications. *BMC Bioinformatics* 10, 421 (2009). [PubMed: 20003500]
51. Vander Heiden JA et al. pRESTO: a toolkit for processing high-throughput sequencing raw reads of lymphocyte receptor repertoires. *Bioinformatics* 30, 1930–1932 (2014). [PubMed: 24618469]
52. Jiang R et al. Thymus-derived B cell clones persist in the circulation after thymectomy in myasthenia gravis. *Proc. Natl Acad. Sci. USA* 117, 30649–30660 (2020). [PubMed: 33199596]
53. Li W & Godzik A Cd-hit: a fast program for clustering and comparing large sets of protein or nucleotide sequences. *Bioinformatics* 22, 1658–1659 (2006). [PubMed: 16731699]
54. Ye J, Ma N, Madden TL & Ostell JM IgBLAST: an immunoglobulin variable domain sequence analysis tool. *Nucleic Acids Res.* 41, W34–W40 (2013). [PubMed: 23671333]
55. Giudicelli V, Chaume D & Lefranc MP IMGT/GENE-DB: a comprehensive database for human and mouse immunoglobulin and T cell receptor genes. *Nucleic Acids Res.* 33, D256–D261 (2005). [PubMed: 15608191]
56. Gupta NT et al. Change-O: a toolkit for analyzing large-scale B cell immunoglobulin repertoire sequencing data. *Bioinformatics* 31, 3356–3358 (2015). [PubMed: 26069265]
57. Gadala-Maria D, Yaari G, Uduman M & Kleinstein SH Automated analysis of high-throughput B-cell sequencing data reveals a high frequency of novel immunoglobulin V gene segment alleles. *Proc. Natl Acad. Sci. USA* 112, E862–E870 (2015). [PubMed: 25675496]
58. Gupta NT et al. Hierarchical clustering can identify B cell clones with high confidence in Ig repertoire sequencing data. *J. Immunol* 198, 2489–2499 (2017). [PubMed: 28179494]
59. Zhou JQ & Kleinstein SH Cutting edge: Ig H chains are sufficient to determine most B cell clonal relationships. *J. Immunol* 203, 1687–1692 (2019). [PubMed: 31484734]
60. Bashford-Rogers RJM et al. Network properties derived from deep sequencing of human B-cell receptor repertoires delineate B-cell populations. *Genome Res.* 23, 1874–1884 (2013). [PubMed: 23742949]
61. Csardi G & Nepusz T The igraph software package for complex network research. *InterJournal Complex Syst.* 1695, 1–9 (2006).




Fig. 1|. Plasmablast and antibody response to SARS-CoV-2 immunization.

a, Study design. Forty-one healthy adult volunteers (ages 28–73, 8 with a history of SARS-CoV-2 infection) were enrolled and received the BNT162b2 mRNA SARS-CoV-2 vaccine. Blood was collected before immunization, and at 3, 4, 5, 7 and 15 weeks after immunization. For 14 participants (ages 28–52, none with a history of SARS-CoV-2 infection), FNAs of ipsilateral axillary lymph nodes (LNs) were collected at 3, 4, 5, 7 and 15 weeks after immunization. **b**, **c**, ELISpot quantification of S-binding IgG- (**b**) and IgA- (**c**) secreting plasmablasts (PBs) in blood at baseline, and at 3, 4, 5 and 7 weeks after immunization in participants without (red) and with (black) a history of SARS-CoV-2

infection. **d**, Plasma IgG titres against SARS-CoV-2 S (left) and the RBD of S (right) measured by ELISA in participants without (red) and with (black) a history of SARS-CoV-2 infection at baseline, and at 3, 4, 5, 7 and 15 weeks after immunization. Dotted lines indicate limits of detection. Symbols at each time point in **b–d** represent one sample ($n = 41$). Results are from one experiment performed in duplicate.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Fig. 2|. Germinal centre B cell response to SARS-CoV-2 immunization.

a, Representative colour Doppler ultrasound image of two draining lymph nodes ('1' and '2') adjacent to the axillary vein 'LAX V' 5 weeks after immunization. **b, c**, Representative flow cytometry plots of BCL6 and CD38 staining on $IgD^{low}CD19^{+}CD3^{-}$ live singlet lymphocytes in FNA samples (**b**; LN1, top row; LN2, bottom row) and S staining on $BCL6^{+}CD38^{int}$ germinal centre B cells in tonsil and FNA samples (**c**) at the indicated times after immunization. **d, e**, Kinetics of total (blue) and S^{+} (white) germinal centre (GC) B cells as gated in **b** and **c** (**d**) and S-binding per cent of germinal centre B cells (**e**) from FNA of draining lymph nodes. Symbols at each time point represent one FNA sample; square symbols denote the second lymph node sampled ($n = 14$). Horizontal lines indicate the median.




Fig. 3|. Clonal analysis of germinal centre response to SARS-CoV-2 immunization.
a, Binding of monoclonal antibodies (mAbs) generated from germinal centre B cells to SARS-CoV-2 S, N-terminal domain (NTD) of S, RBD, or S proteins of betacoronavirus OC43 or HKU1, measured by ELISA. Results are from one experiment performed in duplicate. Baseline for area under the curve was set to the mean + three times the s.d. of background binding to bovine serum albumin. **b**, Clonal relationship of sequences from S-binding germinal centre-derived monoclonal antibodies (cyan) to sequences from bulk repertoire analysis of plasmablasts from PBMCs (red) and germinal centre B cells (blue) sorted 4 weeks after immunization. Each clone is visualized as a network in

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

which each node represents a sequence and sequences are linked as a minimum spanning tree of the network. Symbol shape indicates sequence isotype: IgG (circle), IgA (star) and IgM (square); symbol size corresponds to sequence count. **c, d**, Comparison of nucleotide mutation frequency in *IGHV* genes of naive B cells sorted from individuals vaccinated with influenza virus vaccine¹⁹ (grey) to clonal relatives of S-binding monoclonal antibodies among plasmablasts sorted from PBMCs and germinal centre B cells 4 weeks after immunization (green) in indicated participants (**c**) and between clonal relatives of S-binding monoclonal antibodies cross-reactive (purple) or not (teal) to seasonal coronavirus S proteins among plasmablasts sorted from PBMCs and germinal centre B cells 4 weeks after immunization (**d**). Horizontal lines and error bars indicate the median and interquartile range. Sequence counts were 2,553 (naive), 199 (participant 07), 6 (participant 20), 240 (participant 22), 54 (cross-reactive) and 391 (not cross-reactive). *P* values from two-sided Kruskal–Wallis test with Dunn’s post-test between naive B cells and S-binding clones (**c**) or two-sided Mann–Whitney *U* test (**d**).